Palisades Therapeutics Announces New Anti-Cancer Drug-PT162, a p53-Reactivating Cell Cycle Checkpoint Inhibitor

Newly Patented PT162 Induces Cancer Cell Cycle Arrest and/or Apoptosis by Restoring DNA-Binding Activity of Mutant p53 Protein

Related Keywords

New York ,United States ,Palisades ,Cliffside ,Neil Theise ,Pfizer Inc ,National Cancer Institute ,Bristol Myers Squibb Company ,Cancer Institute ,Cancer Cell Cycle Arrest ,Binding Activity ,Palisades Therapeutics ,Palisades Therapeutic ,Pt162 ,Dr Neil Theise ,